vs

Side-by-side financial comparison of Cheer Holding, Inc. (CHR) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $71.0M, roughly 1.1× Cheer Holding, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -0.1%).

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CHR vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.1× larger
PBYI
$75.5M
$71.0M
CHR
Growing faster (revenue YoY)
PBYI
PBYI
+27.8% gap
PBYI
27.7%
-0.1%
CHR

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CHR
CHR
PBYI
PBYI
Revenue
$71.0M
$75.5M
Net Profit
$7.8M
Gross Margin
70.7%
69.3%
Operating Margin
11.7%
22.7%
Net Margin
10.9%
Revenue YoY
-0.1%
27.7%
Net Profit YoY
-37.5%
EPS (diluted)
$0.67
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHR
CHR
PBYI
PBYI
Q4 25
$75.5M
Q3 25
$54.5M
Q2 25
$71.0M
$52.4M
Q1 25
$46.0M
Q4 24
$59.1M
Q3 24
$80.5M
Q2 24
$71.1M
$47.1M
Q1 24
$43.8M
Net Profit
CHR
CHR
PBYI
PBYI
Q4 25
Q3 25
$8.8M
Q2 25
$7.8M
$5.9M
Q1 25
$3.0M
Q4 24
Q3 24
$20.3M
Q2 24
$12.4M
$-4.5M
Q1 24
$-4.8M
Gross Margin
CHR
CHR
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
70.7%
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
73.4%
77.4%
Q1 24
75.5%
Operating Margin
CHR
CHR
PBYI
PBYI
Q4 25
22.7%
Q3 25
17.6%
Q2 25
11.7%
12.7%
Q1 25
8.7%
Q4 24
22.6%
Q3 24
27.4%
Q2 24
16.4%
-4.6%
Q1 24
-5.3%
Net Margin
CHR
CHR
PBYI
PBYI
Q4 25
Q3 25
16.2%
Q2 25
10.9%
11.2%
Q1 25
6.5%
Q4 24
Q3 24
25.2%
Q2 24
17.5%
-9.6%
Q1 24
-11.0%
EPS (diluted)
CHR
CHR
PBYI
PBYI
Q4 25
$0.26
Q3 25
$0.17
Q2 25
$0.67
$0.12
Q1 25
$0.06
Q4 24
$0.40
Q3 24
$0.41
Q2 24
$1.23
$-0.09
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHR
CHR
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$322.1M
$130.3M
Total Assets
$362.7M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHR
CHR
PBYI
PBYI
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$186.1M
$96.8M
Q1 24
$107.2M
Total Debt
CHR
CHR
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
CHR
CHR
PBYI
PBYI
Q4 25
$130.3M
Q3 25
$115.3M
Q2 25
$322.1M
$104.7M
Q1 25
$97.1M
Q4 24
$92.1M
Q3 24
$71.1M
Q2 24
$286.1M
$48.5M
Q1 24
$51.0M
Total Assets
CHR
CHR
PBYI
PBYI
Q4 25
$216.3M
Q3 25
$202.9M
Q2 25
$362.7M
$194.9M
Q1 25
$196.2M
Q4 24
$213.3M
Q3 24
$220.7M
Q2 24
$333.2M
$205.0M
Q1 24
$214.1M
Debt / Equity
CHR
CHR
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHR
CHR
PBYI
PBYI
Operating Cash FlowLast quarter
$3.9M
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
0.51×
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHR
CHR
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$3.9M
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$-6.7M
$1.0M
Q1 24
$11.2M
Free Cash Flow
CHR
CHR
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
CHR
CHR
PBYI
PBYI
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
CHR
CHR
PBYI
PBYI
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CHR
CHR
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
0.51×
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
-0.54×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons